GlassScriptPhysician profile
Carlos Pena
NPI 1669435988
$6,651.43
in general payments reported to CMS, 2019-2025
28 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $433 · 2021: $1,138 · 2022: $925 · 2023: $1,654 · 2024: $1,604 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549 · Education: $43.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,549.07 |
| Education | $43.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $985.34 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $972.11 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $685.90 | 2020-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $639.51 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $581.76 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $548.85 | 2021-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $519.78 | 2019-2025 | Jynarque |
| Amgen INC. | $435.70 | 2019-2024 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $267.48 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $135.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $116.11 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.25 | 2024 | Jardiance |
| Amniox Medical, INC. | $101.28 | 2020 | |
| Calliditas Therapeutics US INC. | $84.92 | 2023-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $67.78 | 2022-2023 | Benlysta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $62.60 | 2022-2023 | |
| Ardelyx, INC. | $43.39 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $41.07 | 2023 | Velphoro |
| Takeda Pharmaceuticals U.S.A., INC. | $38.70 | 2023 | Livtencity |
| Janssen Biotech, INC. | $34.47 | 2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $25.55 | 2021-2022 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Therapeuticsmd, INC. | $22.61 | 2020 | |
| Shire North American Group INC | $20.87 | 2019 | |
| Trisalus Life Sciences, INC. | $20.78 | 2024 | Trinav Infusion System |
| Novo Nordisk INC | $20.66 | 2023 | Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $20.53 | 2023 | |
| Opko Pharmaceuticals, LLC | $19.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.